News – Page 1095 – Endpoints News

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

8 years ago

FDA derails Acorda's marketing pitch, creating a crisis as flagship drug founders

8 years ago

Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen

8 years ago

AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson's deal

8 years ago

Merck hits a bloop single in an epic PhIII CETP cardio contest. Now what?

8 years ago

Bayer, J&J eye blockbuster supplemental OK for Xarelto; SetPoint raises $30M for bioelectronics

8 years ago

Viking leads a $46M raise for a struggling aTyr Pharma

8 years ago

Aveo takes a big step forward as comeback plan delivers EU OK for tivo

8 years ago

CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effort

8 years ago

Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma

8 years ago

Novartis team scores a pioneering first in cardio R&D. But can they sell it?

8 years ago

Novartis recruits a global digital chief; Shire CFO jumps ship

8 years ago

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

8 years ago

After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine

8 years ago

Novartis returns to the discount aisle, buys Xoma's failed PhIII drug for $31M

8 years ago

Regenxbio bags one of its gene therapy vector partners, buying out a struggling Dimension

8 years ago

Pfizer has found a stylish new home for its HQ in Manhattan — report

8 years ago

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

8 years ago

Adamas wins its first FDA OK, setting up market launch for a reformulated Parkinson’s drug

8 years ago

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

8 years ago

On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII

8 years ago

Troubled ImmunoCellular slashes costs, jobs in restructuring; Accelerated Pharma dumps struggling IPO effort

8 years ago

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

8 years ago

Meet Bertrand Bodson, Novartis’ new global digital strategy maestro for all things Big Pharma

8 years ago

First page Previous page 1092 1093 109410951096 1097 1098 Next page Last page